Gufic Biosciences Limited — Important, 31-01-2025: General Updates

Gufic Biosciences Limited has secured a patent in Europe for a freeze-dried parenteral composition of Omadacycline Tosylate, which boasts improved stability. The patent, effective from June 5, 2023, is granted for a term of 20 years. Omadacycline Tosylate is already approved in the United States for treating Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This development strengthens the company's intellectual property portfolio and positions it for potential growth in international markets, particularly in areas requiring advanced formulations for antibiotic treatments. Investors should monitor this opportunity as it may enhance Gufic’s market presence and revenue potential.